Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F2 | P00734 | 15/20 | 0.50 |
| ▸ | F10 | P00742 | 4/20 | 0.50 |
| ▸ | CTRC | Q99895 | 4/20 | 0.41 |
| ▸ | PRSS2 | P07478 | 4/20 | 0.39 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.39 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.39 |
| ▸ | CACNA1B | Q00975 | 2/20 | 0.39 |
| ▸ | CA12 | O43570 | 1/20 | 0.35 |
| ▸ | CA1 | P00915 | 1/20 | 0.35 |
| ▸ | CA2 | P00918 | 1/20 | 0.35 |
| ▸ | CA9 | Q16790 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5866143 | 0.91 | F2 (0.47) | F2F10CTRCPRSS2PRSS1 | |
| SCHEMBL5866238 | 0.89 | F2 (0.51) | F2F10CTRCPRSS2PRSS1 | |
| SCHEMBL5866280 | 0.87 | F2 (0.41) | F2F10CTRCPRSS2CA12 | |
| SCHEMBL5866285 | 0.87 | F2 (0.41) | F2F10CTRCPRSS2CA12 | |
| SCHEMBL5866370 | 0.84 | F2 (0.58) | F2F10CTRCPRSS2 | |
| SCHEMBL5866141 | 0.79 | F2 (0.39) | F2F10CTRCPRSS2CA12 | |
| SCHEMBL5866147 | 0.79 | F2 (0.39) | F2F10CTRCPRSS2CA12 | |
| SCHEMBL5866115 | 0.79 | F2 (0.49) | F2F10CTRCPRSS2PRSS1 | |
| SCHEMBL7607232 | 0.76 | F2 (0.82) | F2F10CTRCPRSS2 | |
| SCHEMBL7606269 | 0.76 | F2 (0.51) | F2F10CTRCPRSS2PRSS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7074820-B2 | Amidino derivatives and their use as thrombin inhibitors | ASTRAZENECA AB (SE) | 2006-07-11 | — | — | US | disclosed |
| EP-0917528-B1 | NEW AMIDINO DERIVATIVES AND THEIR USE AS THROMBIN INHIBITORS | ASTRAZENECA AB (SE) | 2002-09-18 | — | — | EP | disclosed |
| US-20020040043-A1 | Amidino derivatives and their use as thrombin inhibitors | ANTONSSON THOMAS (SE) | 2002-04-04 | — | — | US | disclosed |
| US-6221898-B1 | ANTICOAGULANTS | ASTRA AKTIEBOLAG (SE) | 2001-04-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020040043-A1 | Amidino derivatives and their use as thrombin inhibitors | SERPINC1, F2, SERPINE1 | F2 2/4885F10 55/4885CTRC 49/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.